What is AGX-201 used for?

AGX-201 is indicated for Type 2 diabetes.

AGX-201 is developed by AgoneX Biopharmaceuticals, Inc..

What are the side effects of AGX-201?

Common side effects include Increased risk of diabetic ketoacidosis.

Last reviewed 2026-04-23 · How we verify

AGX-201

AgoneX Biopharmaceuticals, Inc. · Phase 2 active Small molecule

AGX-201 is a small molecule that targets the SGLT2 receptor.

AGX-201 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.

At a glance

Generic name	AGX-201
Sponsor	AgoneX Biopharmaceuticals, Inc.
Drug class	SGLT2 inhibitor
Target	SGLT2
Modality	Small molecule
Therapeutic area	Diabetes
Phase	Phase 2

Mechanism of action

By inhibiting the SGLT2 receptor, AGX-201 reduces glucose reabsorption in the kidneys, leading to decreased blood glucose levels. This mechanism is particularly useful in the treatment of type 2 diabetes.

Approved indications

Type 2 diabetes

Common side effects

Increased risk of diabetic ketoacidosis

Key clinical trials

A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Subcutaneous AGX-201 for Migraine Prophylaxis (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results